Kezar Life Sciences, Inc. (KZR)

Kezar Life Sciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-101.33	-101.87	-68.24	-54.63	-41.74	-35.09
Depreciation & Amortization	1.07	1.07	1.02	1.51	1.54	1.3
Share-Based Compensation	17.31	18.14	14.01	7.6	4.94	4.01
Other Operating Activities	-0.69	1.02	-5.64	3.09	-1.69	-0.1
Operating Cash Flow	-83.65	-81.65	-58.85	-42.44	-36.95	-29.88
Capital Expenditures	-1.51	-1.81	-1.58	-0.32	-0.19	-0.61
Change in Investments	81.57	77.85	-89.81	-28.13	-56.3	21.03
Investing Cash Flow	80.06	76.05	-91.39	-28.44	-56.5	20.42
Share Issuance / Repurchase	0.48	0.64	127.86	103.05	99.64	0.27
Debt Issued / Paid	0	0	0	9.53	0	0
Financing Cash Flow	0.48	0.64	127.86	112.59	99.64	0.27
Exchange Rate Effect	0	-0	-0.05	-0.05	0.08	-0.05
Net Cash Flow	-3.1	-4.96	-22.43	41.65	6.28	-9.23
Free Cash Flow	-85.16	-83.45	-60.42	-42.75	-37.14	-30.48
Free Cash Flow Margin	-1216.50%	-1192.14%	-	-	-	-
Free Cash Flow Per Share	-1.17	-1.15	-0.90	-0.81	-0.84	-1.60

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).